Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Press Release

Dicerna to Participate in Upcoming Investor Conferences

Feb 6, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences.

  • SunTrust Rare Disease Day - Dr. Fambrough will participate in the SunTrust Robinson Humphrey 2018 Orphan Drug Day on Tuesday, February 13, 2018, at the JW Marriott Essex House in New York.
  • Leerink Global Healthcare Conference - Dr. Fambrough will participate in a fireside chat on Wednesday, February 14, 2018 at 1:00 p.m. ET at the Lotte New York Palace in New York.

A live webcast of the fireside chat at the Leerink Global Healthcare Conference can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Investors:
Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
or
Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media